Raquel Izumi

7.2k total citations · 1 hit paper
72 papers, 2.6k citations indexed

About

Raquel Izumi is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Raquel Izumi has authored 72 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 32 papers in Pathology and Forensic Medicine and 25 papers in Oncology. Recurrent topics in Raquel Izumi's work include Chronic Lymphocytic Leukemia Research (44 papers), Lymphoma Diagnosis and Treatment (28 papers) and Advanced Breast Cancer Therapies (8 papers). Raquel Izumi is often cited by papers focused on Chronic Lymphocytic Leukemia Research (44 papers), Lymphoma Diagnosis and Treatment (28 papers) and Advanced Breast Cancer Therapies (8 papers). Raquel Izumi collaborates with scholars based in United States, United Kingdom and Germany. Raquel Izumi's co-authors include Ahmed Hamdy, Richard R. Furman, Jeff P. Sharman, Nathan Fowler, Ranjana H. Advani, Joseph J. Buggy, Barbara Grant, Sonali M. Smith, Betty Chang and Thomas E. Boyd and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Raquel Izumi

71 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2012 848 citations Ranjana H. Advani, Joseph J. Buggy et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raquel Izumi United States	21	1.8k	1.5k	644	638	580	72	2.6k
Ahmed Hamdy United States	18	1.9k 1.1×	1.6k 1.0×	732 1.1×	668 1.0×	527 0.9×	60	2.5k
Loree Larratt Canada	28	1.3k 0.7×	1.0k 0.7×	831 1.3×	1.2k 1.9×	625 1.1×	80	3.1k
Aleksander B. Skotnicki Poland	20	1.2k 0.6×	792 0.5×	481 0.7×	856 1.3×	461 0.8×	130	2.3k
Andrew R. Pettitt United Kingdom	27	1.7k 0.9×	1.4k 0.9×	827 1.3×	367 0.6×	789 1.4×	106	2.7k
Bertold Emmerich Germany	32	1.7k 0.9×	1.3k 0.9×	1.2k 1.8×	916 1.4×	759 1.3×	114	3.5k
Massimo Gentile Italy	25	898 0.5×	640 0.4×	509 0.8×	665 1.0×	593 1.0×	177	2.1k
Anders Österborg Sweden	28	994 0.5×	986 0.6×	1.2k 1.9×	1.3k 2.0×	1.0k 1.7×	78	3.4k
Todd Busman United States	20	681 0.4×	514 0.3×	415 0.6×	459 0.7×	655 1.1×	42	2.6k
S.A. Johnson United Kingdom	21	774 0.4×	587 0.4×	716 1.1×	425 0.7×	456 0.8×	35	2.0k
Ewa Lech‐Marańda Poland	25	511 0.3×	479 0.3×	437 0.7×	414 0.6×	421 0.7×	134	1.7k

Countries citing papers authored by Raquel Izumi

Since Specialization

Citations

This map shows the geographic impact of Raquel Izumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raquel Izumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raquel Izumi more than expected).

Fields of papers citing papers by Raquel Izumi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raquel Izumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raquel Izumi. The network helps show where Raquel Izumi may publish in the future.

Co-authorship network of co-authors of Raquel Izumi

This figure shows the co-authorship network connecting the top 25 collaborators of Raquel Izumi. A scholar is included among the top collaborators of Raquel Izumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raquel Izumi. Raquel Izumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frigault, Melanie M., Beatrix Stelte‐Ludwig, Amy J. Johnson, et al.. (2024). Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. SHILAP Revista de lepidopterología. 2(1). 100050–100050. 1 indexed citations

Wiedmann, Mareike M., Beatrix Stelte‐Ludwig, Harvey Wong, et al.. (2024). Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment. Frontiers in Pharmacology. 15. 1358393–1358393. 2 indexed citations

Lerchen, Hans‐Georg, Beatrix Stelte‐Ludwig, Mélanie Héroult, et al.. (2023). Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors. Cancers. 15(17). 4381–4381. 8 indexed citations

Frigault, Melanie M., Harvey Wong, Beatrix Stelte‐Ludwig, et al.. (2023). Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Research Communications. 3(11). 2268–2279. 7 indexed citations

Frigault, Melanie M., Amy J. Johnson, Joseph Birkett, et al.. (2023). Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children. Cancer Research. 83(7_Supplement). 1558–1558. 1 indexed citations

Schomber, Tibor, Beatrix Stelte‐Ludwig, Oliver von Ahsen, et al.. (2023). Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model. Blood. 142(Supplement 1). 2809–2809. 1 indexed citations

Diamond, Jennifer R., Valentina Boni, Emerson A. Lim, et al.. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research. 28(7). 1285–1293. 30 indexed citations

Byrd, John C., Jennifer A. Woyach, Richard R. Furman, et al.. (2021). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 137(24). 3327–3338. 63 indexed citations

Rogers, Kerry A., Philip A. Thompson, John N. Allan, et al.. (2021). Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 106(9). 2364–2373. 76 indexed citations

10.

Woyach, Jennifer A., James S. Blachly, Kerry A. Rogers, et al.. (2020). Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Cancer Discovery. 10(3). 394–405. 57 indexed citations

11.

Cheung, Jean, Michael Gulrajani, Erika M. Gaglione, et al.. (2020). Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research. 26(12). 2800–2809. 21 indexed citations

12.

Awan, Farrukh T., Anna Schuh, Jennifer R. Brown, et al.. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 3(9). 1553–1562. 144 indexed citations

13.

Barr, Paul M., Stephen D. Smith, Mark Roschewski, et al.. (2018). Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. Journal of Clinical Oncology. 36(15_suppl). 7518–7518. 5 indexed citations

14.

Niemann, Carsten Utoft, Helena Mora-Jensen, Eman L. Dadashian, et al.. (2017). Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical Cancer Research. 23(19). 5814–5823. 25 indexed citations

15.

Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations

16.

Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841. 121 indexed citations

17.

Harrington, Bonnie K., Heather L. Gardner, Raquel Izumi, et al.. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE. 11(7). e0159607–e0159607. 43 indexed citations

18.

Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations

19.

Advani, Ranjana H., Joseph J. Buggy, Jeff P. Sharman, et al.. (2012). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology. 31(1). 88–94. 848 indexed citations breakdown →

20.

Izumi, Raquel, et al.. (2001). Nucleolin stimulates viral internal ribosome entry site-mediated translation. Virus Research. 76(1). 17–29. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact